このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Low-Dose Versus Standard-Dose Tenecteplase for Acute Minor Ischemic Stroke With Disabling Deficits (MILD-EFFECT)

2026年11月17日 更新者:Shandong Provincial Hospital

Low-Dose Recombinant Human Tenecteplase Tissue-Type Plasminogen Activator for Injection in Acute Minor Ischemic Stroke With Disabling Deficits: The MILD-EFFECT Multicenter Randomized Controlled Trial

This study will compare two doses of a clot-dissolving medicine called tenecteplase (TNK), specifically recombinant human TNK tissue-type plasminogen activator for injection (rhTNK-tPA), in adults with a mild ischemic stroke that causes disabling symptoms. An ischemic stroke occurs when a blood clot blocks blood flow to the brain. Even a mild stroke can cause problems that prevent a person from carrying out basic daily activities or returning to work.

The main question is whether a lower dose of rhTNK-tPA helps patients recover nearly as well as the standard dose, within a predefined acceptable difference. The study will also compare bleeding and other side effects between the two doses.

Up to 1,324 participants at multiple hospitals will be randomly assigned to receive either the lower dose (0.18 mg/kg, up to 16 mg) or the standard dose (0.25 mg/kg, up to 25 mg). Each participant will receive one injection into a vein within 4.5 hours of stroke onset, along with usual stroke care. Participants and treating doctors will know which dose is given, but the assessors evaluating recovery will not.

Participants will be followed for approximately 90 days. Researchers will assess recovery, ability to carry out daily activities, quality of life, bleeding, and other medical problems. The main outcome is the proportion of participants who have no symptoms or no significant disability at about 90 days after treatment.

調査の概要

状態

募集

条件

介入・治療

研究の種類

介入

入学 (推定)

1324

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:QinJian Sun
  • 電話番号:86-0531-68773275
  • メール:sqj1210@163.com

研究場所

    • Shandong
      • Jinan、Shandong、中国、250021
        • 募集
        • Shandong Provincial Hospital Affiliated to Shandong First Medical University
        • コンタクト:
          • Qinjian Sun, MD
          • 電話番号:+86-0531-68773275
          • メール:sqj1210@163.com
        • 主任研究者:
          • QinJian Sun

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Age ≥18 years.
  2. Clinical diagnosis of acute ischemic stroke with a baseline National Institutes of Health Stroke Scale (NIHSS) score ≤5.
  3. Presence of clearly disabling neurological deficits that persist and prevent the participant from independently performing at least one basic activity of daily living (including bathing, dressing, walking, toileting, personal hygiene, and eating) and/or returning to their previous work.
  4. Time from stroke onset to treatment <4.5 hours, with onset defined as the time of symptom onset or the last known well time.
  5. Pre-stroke modified Rankin Scale (mRS) score ≤1.
  6. Voluntary participation and written informed consent provided by the participant or their legally authorized representative.

Exclusion Criteria:

  1. Intracranial hemorrhage, including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural hematoma, or epidural hematoma.
  2. NIHSS item 1a score >2.
  3. Planned endovascular treatment before randomization.
  4. History of intracranial hemorrhage, or presence of an intra-axial intracranial tumor, giant intracranial aneurysm, or arteriovenous malformation.
  5. History of stroke within the preceding 3 months.
  6. Recent anticoagulant treatment with coagulation parameters that do not meet the safety requirements for thrombolysis.
  7. Active internal bleeding or an acute bleeding tendency, including a platelet count <100 × 10⁹/L.
  8. Concomitant bacterial endocarditis, pericarditis, acute pancreatitis, or other severe, difficult-to-control infections.
  9. History of major trauma (e.g., severe head injury within the preceding 3 months), surgery or invasive procedures (e.g., intracranial or spinal canal surgery within the preceding 3 months, major surgery within the preceding 2 weeks, or arterial puncture at a site not amenable to compression within the preceding week), or bleeding (e.g., gastrointestinal or urinary tract bleeding within the preceding 3 weeks).
  10. Persistent uncontrolled hypertension despite active antihypertensive treatment: systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥100 mmHg.
  11. Blood glucose <2.8 mmol/L or >22.22 mmol/L. Eligibility may be reassessed after correction of blood glucose if clearly disabling neurological deficits associated with minor stroke persist and the participant meets the diagnostic criteria for acute ischemic stroke and the eligibility requirements for intravenous thrombolysis.
  12. Postictal paresis (Todd's paresis), or other neurological or psychiatric conditions resulting in inability or unwillingness to cooperate.
  13. Known allergy to the active ingredient rhTNK-tPA or any of its excipients.
  14. Current participation in another interventional medical device or drug study, or completion of participation in such a study less than 30 days previously.
  15. Pregnancy, breastfeeding, or unwillingness of a female participant to use effective contraception during the trial.
  16. Other serious diseases associated with a life expectancy of less than 6 months.
  17. Any other condition that, in the investigator's judgment, may substantially increase bleeding risk, interfere with study assessments, or render the participant unsuitable for the trial.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Low-Dose Tenecteplase (rhTNK-tPA)

Participants will receive rhTNK-tPA at 0.18 mg/kg, with a maximum dose of 16 mg, administered as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.

Tenecteplase (rhTNK-tPA) will be administered at 0.18 mg/kg, with a maximum dose of 16 mg, as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.

他の名前:
  • rhTNK-tPA
  • Recombinant Human TNK Tissue-Type Plasminogen Activator for Injection
アクティブコンパレータ:Standard-Dose Tenecteplase (rhTNK-tPA)

Participants will receive rhTNK-tPA at 0.25 mg/kg, with a maximum dose of 25 mg, administered as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.

Tenecteplase (rhTNK-tPA) will be administered at 0.25 mg/kg, with a maximum dose of 25 mg, as a single intravenous bolus over 5 to 10 seconds within 4.5 hours after stroke onset. Participants will also receive standard stroke care according to current clinical guidelines.

他の名前:
  • rhTNK-tPA
  • Recombinant Human TNK Tissue-Type Plasminogen Activator for Injection

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Proportion of Participants With a Modified Rankin Scale (mRS) Score of 0-1
時間枠:90 ± 7 days after randomization

The modified Rankin Scale (mRS) measures functional disability after stroke. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. An mRS score of 0-1 indicates no significant disability.

90 ± 7 days after randomization

二次結果の測定

結果測定
メジャーの説明
時間枠
Proportion of Participants With a Modified Rankin Scale (mRS) Score of 0-2
時間枠:90 ± 7 days after randomization

The modified Rankin Scale (mRS) measures functional disability after stroke. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. An mRS score of 0-2 indicates functional independence.

90 ± 7 days after randomization
Distribution of Modified Rankin Scale (mRS) Scores
時間枠:90 ± 7 days after randomization

The modified Rankin Scale (mRS) measures functional disability after stroke. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. The distribution across all seven categories (0-6) will be assessed.

90 ± 7 days after randomization
Proportion of Participants With a National Institutes of Health Stroke Scale (NIHSS) Score of 0-1
時間枠:22-36 hours after randomization and at day 7 ± 1 or discharge, whichever occurs first

The National Institutes of Health Stroke Scale (NIHSS) assesses neurological deficits after stroke. Total scores range from 0 to 42, with higher scores indicating greater neurological impairment. An NIHSS score of 0-1 indicates no or minimal neurological deficits.

22-36 hours after randomization and at day 7 ± 1 or discharge, whichever occurs first
Proportion of Participants With an Increase From Baseline of ≥2 Points in Total NIHSS Score or ≥1 Point in Any Motor Item Score
時間枠:Baseline to 22-36 hours after randomization and to day 7 ± 1 or discharge, whichever occurs first

The National Institutes of Health Stroke Scale (NIHSS) assesses neurological deficits after stroke. Total scores range from 0 to 42, with higher scores indicating greater neurological impairment. Each motor item is scored from 0 to 4. Neurological worsening is defined as an increase of ≥2 points in the total NIHSS score or ≥1 point in any motor item compared with baseline.

Baseline to 22-36 hours after randomization and to day 7 ± 1 or discharge, whichever occurs first
Proportion of Participants With a Decrease From Baseline of ≥2 Points in Total NIHSS Score or ≥1 Point in Any Motor Item Score
時間枠:Baseline to 22-36 hours after randomization and to day 7 ± 1 or discharge, whichever occurs first

The National Institutes of Health Stroke Scale (NIHSS) assesses neurological deficits after stroke. Total scores range from 0 to 42, with higher scores indicating greater neurological impairment. Each motor item is scored from 0 to 4. Neurological improvement is defined as a decrease of ≥2 points in the total NIHSS score or ≥1 point in any motor item compared with baseline.

Baseline to 22-36 hours after randomization and to day 7 ± 1 or discharge, whichever occurs first
Proportion of Participants With a COSMOS score Grade of 0-1
時間枠:90 ± 7 days after randomization

The Canadian Outcome Scale for Minor Stroke (COSMOS) assesses functional outcomes after minor stroke, including limitations in daily activities and participation in meaningful activities. Scores range from 0 (no symptoms) to 6 (loss of independence or worse), with higher scores indicating worse outcomes. The proportion of participants with a COSMOS grade of 0-1 will be assessed.

90 ± 7 days after randomization
COSMOS Score
時間枠:90 ± 7 days after randomization

The Canadian Outcome Scale for Minor Stroke (COSMOS) assesses functional outcomes after minor stroke, including limitations in daily activities and participation in meaningful activities. Scores range from 0 (no symptoms) to 6 (loss of independence for an instrumental or basic activity of daily living or worse), with higher scores indicating worse outcomes. The distribution of COSMOS grades from 0 to 6 at 90 days will be assessed.

90 ± 7 days after randomization
Health-Related Quality of Life Assessed by EQ-5D-3L and EQ VAS
時間枠:90 ± 7 days after randomization

The EuroQol Five-Dimension Three-Level Questionnaire (EQ-5D-3L) assesses health-related quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has three response levels, ranging from 1 (no problems) to 3 (extreme problems or inability to perform the activity), with higher levels indicating worse health status. The accompanying EuroQol Visual Analogue Scale (EQ VAS) assesses self-rated overall health on a scale from 0 (worst imaginable health) to 100 (best imaginable health), with higher scores indicating better health status.

90 ± 7 days after randomization
Incidence of Symptomatic Intracranial Hemorrhage According to ECASS III Criteria Within 36 Hours
時間枠:Within 36 hours after study drug administration

Symptomatic intracranial hemorrhage (sICH) is defined according to the European Cooperative Acute Stroke Study III (ECASS III) criteria as any intracranial hemorrhage associated with neurological deterioration, defined as an increase of ≥4 points in the National Institutes of Health Stroke Scale (NIHSS) score, or resulting in death, with the hemorrhage identified as the predominant cause of neurological deterioration or death.

Within 36 hours after study drug administration
Incidence of Any Intracranial Hemorrhage Within 36 Hours
時間枠:Within 36 hours after study drug administration

Any intracranial hemorrhage is defined as the presence of intracranial bleeding detected by brain computed tomography (CT) or magnetic resonance imaging (MRI), regardless of whether neurological deterioration or clinical symptoms are present. Both symptomatic and asymptomatic intracranial hemorrhages are included.

Within 36 hours after study drug administration
Incidence of Symptomatic Intracranial Hemorrhage According to ECASS III Criteria Within 7 Days
時間枠:Within 7 days after study drug administration

Symptomatic intracranial hemorrhage (sICH) is defined according to the European Cooperative Acute Stroke Study III (ECASS III) criteria as any intracranial hemorrhage associated with neurological deterioration, defined as an increase of ≥4 points in the National Institutes of Health Stroke Scale (NIHSS) score, or resulting in death, with the hemorrhage identified as the predominant cause of neurological deterioration or death. Events occurring within 7 days after study drug administration will be assessed.

Within 7 days after study drug administration
Incidence of Major Extracranial Bleeding According to ISTH Criteria
時間枠:Within 7 days after study drug administration

Major extracranial bleeding is defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria as bleeding outside the cranium meeting at least one of the following: fatal bleeding; symptomatic bleeding in a critical extracranial area or organ, including intraspinal, intraocular, retroperitoneal, intra-articular, or pericardial bleeding, or intramuscular bleeding with compartment syndrome; a decrease in hemoglobin of ≥2 g/dL; or transfusion of ≥2 units of whole blood or red blood cells.

Within 7 days after study drug administration
Proportion of Participants With a Modified Rankin Scale (mRS) Score of 5-6
時間枠:90 ± 7 days after randomization

The modified Rankin Scale (mRS) measures functional disability after stroke. Scores range from 0 (no symptoms) to 6 (death), with higher scores indicating worse outcomes. An mRS score of 5-6 indicates severe disability or death.

90 ± 7 days after randomization
All-Cause Mortality
時間枠:Within 90 days after randomization
Within 90 days after randomization
Proportion of Participants Experiencing at Least One Adverse Event
時間枠:Within 90 days after study drug administration
Within 90 days after study drug administration
Proportion of Participants Experiencing at Least One Serious Adverse Event
時間枠:Within 90 days after study drug administration
Within 90 days after study drug administration

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:QinJian Sun、Shandong Provincial Hospital

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年10月15日

一次修了 (推定)

2029年4月1日

研究の完了 (推定)

2029年7月1日

試験登録日

最初に提出

2026年10月29日

QC基準を満たした最初の提出物

2026年11月17日

最初の投稿 (実際)

2026年11月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年11月17日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。